
Wockhardt Ltd Upgraded to Hold on Strong Financial and Technical Improvements
2026-05-08 08:03:00Wockhardt Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a marked improvement across key parameters including financial performance, valuation, and technical indicators. The pharmaceutical company’s recent quarterly results and evolving market trends have prompted analysts to revise their outlook, signalling cautious optimism amid a competitive sector landscape.
Read full news article
Wockhardt Ltd Technical Momentum Shifts Signal Mildly Bullish Outlook Amid Volatility
2026-05-08 08:01:06Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a recent day decline of 4.85%, the stock’s technical indicators reveal a complex but cautiously optimistic picture, supported by strong weekly momentum and mixed monthly signals.
Read full news article
Wockhardt Ltd Sees Heavy Value Trading Amid Sector Underperformance
2026-05-07 10:00:10Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed significant trading activity on 7 May 2026, with a total traded value exceeding ₹258 crore. Despite this high-value turnover, the stock underperformed its sector and broader market indices, reflecting a complex interplay of investor sentiment and institutional interest.
Read full news article
Wockhardt Ltd Sees Technical Momentum Shift Amid Strong Price Rally
2026-05-07 08:01:09Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical parameters, signalling a transition from a mildly bearish trend to a sideways momentum. Despite this, the stock has surged impressively, gaining 11.9% in a single day and outperforming the broader Sensex across multiple timeframes, reflecting a complex interplay of bullish and bearish technical indicators.
Read full news article
Wockhardt Ltd Valuation Shifts Signal Heightened Price Premium Amid Strong Returns
2026-05-07 08:00:30Wockhardt Ltd has witnessed a significant shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. This change comes amid a robust price rally that has seen the stock surge over 11.9% in a single day, raising questions about its price attractiveness relative to historical and peer benchmarks in the Pharmaceuticals & Biotechnology sector.
Read full news article
Wockhardt Ltd Sees Robust Trading Activity Amid Strong Price Gains
2026-05-06 10:00:06Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 6 May 2026. The stock recorded a significant 7.56% gain on the day, driven by robust institutional participation and a surge in large order flows, signalling renewed investor confidence despite a recent downgrade in its mojo grade.
Read full news article
Wockhardt Ltd Surges 7.11% to Day's High of Rs 1650 — Outperforms Sector by 6.14 Percentage Points
2026-05-06 09:55:44The Sensex edged up 0.33% on 6 May 2026, while Wockhardt Ltd surged 7.11%, reaching an intraday high of Rs 1650. This 6.14-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally rather than a broad market lift.
Read full news articleAre Wockhardt Ltd latest results good or bad?
2026-05-05 19:14:29Wockhardt Ltd's latest financial results for the quarter ended March 2026 highlight a significant operational turnaround for the company. The net profit reached ₹166 crore, reflecting a substantial increase compared to the previous quarter's loss. This marks a notable recovery from prior financial struggles, indicating improved operational efficiency and profitability. The company's revenue also showed positive momentum, with net sales of ₹965 crore, representing an 8.67% increase from the previous quarter and a 29.88% year-on-year growth. This growth is attributed to strengthening demand across its pharmaceutical portfolio and enhanced market penetration. The operating margin improved to 23.32%, the highest in recent quarters, showcasing effective cost management and operational leverage. Wockhardt's transformation from a chronic loss-maker to a profitable entity is underscored by its ability to achieve...
Read full news article
Wockhardt Ltd Reports Outstanding Q4 2026 Performance Amid Strong Financial Trend Reversal
2026-05-05 11:00:05Wockhardt Ltd has delivered an exceptional quarterly performance for March 2026, marking a significant turnaround in its financial trend from very positive to outstanding. The pharmaceutical company’s latest results showcase robust revenue growth, margin expansion, and improved operational metrics, positioning it favourably against both its historical performance and broader market benchmarks.
Read full news articleAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
04-May-2026 | Source : BSESubmission pursuant to Regulation 30 (LODR)Regulations 2015- Press Release
Announcement under Regulation 30 (LODR)-Change in Management
04-May-2026 | Source : BSEChange in Senior Management Personnel.
Board Meeting Outcome for Outcome Of The Board Meeting Held On 4Th May 2026
04-May-2026 | Source : BSEPlease be informed that the Board of Directors of the Company at its meeting held today i.e. 4th May 2026 inter-alia has approved: i. the Audited Financial Results and Financial Statements Standalone & Consolidated) for the quarter and financial year ended 31st March 2026. Kindly find enclosed herewith: a. March 2026 along with Audit Report issued by M/s. M S K C & Associates LLP Statutory Auditors of the Company on the same (enclosed as Annexure I); and b. Declaration on unmodified opinion on Audit Report (enclosed as Annexure II) ii Enabling proposal for raising of funds subject to consent of the shareholders at the ensuing AGM and such approvals and compliances as may be required.Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March 2026
Corporate Actions
No Upcoming Board Meetings
Wockhardt Ltd has declared 200% dividend, ex-date: 17 Nov 16
No Splits history available
No Bonus history available
Wockhardt Ltd has announced 3:10 rights issue, ex-date: 08 Mar 22






